Multicystic kidney disease: a complication of crizotinib.
暂无分享，去创建一个
[1] A. Baron,et al. Drug‐induced reduction in estimated glomerular filtration rate in patients with ALK‐positive non‐small cell lung cancer treated with the ALK inhibitor crizotinib , 2014, Cancer.
[2] C. Marquette,et al. Acute kidney injury following crizotinib administration for non-small-cell lung carcinoma. , 2013, Lung cancer.
[3] Youhua Liu,et al. Activation of hepatocyte growth factor receptor, c-met, in renal tubules is required for renoprotection after acute kidney injury , 2013, Kidney international.
[4] Jing Zhou,et al. Failure to ubiquitinate c-Met leads to hyperactivation of mTOR signaling in a mouse model of autosomal dominant polycystic kidney disease. , 2010, The Journal of clinical investigation.
[5] P. Comoglio,et al. Agonistic monoclonal antibodies against the Met receptor dissect the biological responses to HGF. , 1998, Journal of cell science.